CD44 and cancer: Frequency of CD44+ cells (Figure 4G-H) and expression levels of Cd44 and other cancer stem cell markers Ascl2, Lgr5 and Smoc2 were markedly reduced in Mex3a-deficient tumors (Figure 4I).